Atopic dermatitis (AD) affects up to 20% of children and adults worldwide. To gain a deeper understanding of the pathophysiology of AD, we conducted a large-scale transcriptomic study of AD with deeply sequenced RNA-sequencing samples using long (126-bp) paired-end reads. In addition to the comparisons against previous transcriptomic studies, we conducted in-depth analysis to obtain a high-resolution view of the global architecture of the AD transcriptome and contrasted it with that of psoriasis from the same cohort. By using 147 RNA samples in total, we found striking correlation between dysregulated genes in lesional psoriasis and lesional AD skin with 81% of AD dysregulated genes being shared with psoriasis. However, we described disease-specific molecular and cellular features, with AD skin showing dominance of IL-13 pathways, but with near undetectable IL-4 expression. We also demonstrated greater disease heterogeneity and larger proportion of dysregulated long noncoding RNAs in AD, and illustrated the translational impact, including skin-type classification and drug-target prediction. This study is by far the largest study comparing the AD and psoriasis transcriptomes using RNA sequencing and demonstrating the shared inflammatory components, as well as specific discordant cytokine signatures of these two skin diseases.

INTRODUCTION

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that affects up to 20% of children and adults of different populations (DaVeiga, 2012). It has a complex genetic condition (Paternoster et al., 2015) and is characterized by disturbed epidermal architecture and keratinocyte differentiation, as well as excessive T-cell–mediated inflammation (Boehncke and Schon, 2015; Weidinger and Novak, 2016). While these pathophysiological features are broadly shared with psoriasis, the clinical presentations are mutually exclusive, with opposing genetic effects in shared pathways (Baurecht et al., 2015) and antagonistic immune deviations (Eyerich et al., 2011). While different groups have investigated the AD transcriptome using microarray technology (Choy et al., 2012; Gittler et al., 2012; Quaranta et al., 2014; Rodriguez et al., 2014; Suarez-Farinas et al., 2015), the samples sizes so far have been relatively small compared with those conducted for psoriasis. In addition, AD is a heterogeneous disease that has been proposed to comprise several distinct subtypes (Thijs et al., 2017; Weidinger and Novak, 2016). In contrast, transcriptomic studies, particularly RNA-sequencing (RNA-seq)–based, have been instrumental in identifying transcripts and pathways in psoriasis (Gudjonsson et al., 2010; Li et al., 2014; Swindell et al., 2013; Tsoi et al., 2015), establishing psoriasis as a T-helper type (Th17/IL-23 and TNF-associated disease (Greb et al., 2016; Varshney et al., 2016); and AD-based studies have been mostly limited to lower-resolution microarray-based studies (Choy et al., 2012; Gittler et al., 2012; Guttmann-Yassky et al., 2009; Nomura et al., 2003; Rodriguez et al., 2014; Suarez-Farinas et al., 2011). There have been limited RNA-seq–based small studies conducted on AD skin (Suarez-Farinas et al., 2015), and a small number of microarray-based studies have attempted to disentangle the specific transcriptomic signatures of psoriasis.
versus AD (Choy et al., 2012; Guttman-Yassky et al., 2009; Nomura et al., 2003; Quaranta et al., 2014). Here, we performed RNA-seq by sequencing in high-depth the transcriptomes of 147 samples from carefully matched and tightly defined cohorts of AD patients, psoriasis patients, and healthy controls, whom were recruited within an ongoing investigator-initiated clinical study to identify shared and distinct disease mechanisms of AD and psoriasis. We hypothesized that by integrating deep sequencing–based transcriptome profiling with systems biology analysis, we are able to provide deep characterization for the expression signatures for AD, and by including psoriasis samples in the analysis, we can reveal the distinct molecular features of uninvolved and lesional skin of AD that have not been described previously.

**RESULTS**

**Transcriptomic architecture and components of AD**

Our cohort provides the largest number of co-sequenced AD and psoriasis samples of uninvolved and lesional skin to date (Supplementary Tables S1–S3 online) and obtained on average >31 million read (126 bp) pairs per sample. With 80% of uniquely mapped reads, we detected expression of 31,364 genes. While the first two principal components computed using the whole transcriptome can separate the normal/uninvolved skin versus lesional skin samples, they were not adequate to provide clean separation for psoriasis and AD lesional skin (Supplementary Figure S1 online). However, the top three principal components could provide a near perfect separation between the different lesional skin types (Figure 1a). AD has been regarded a heterogeneous clinical condition (Weidinger and Novak, 2016), and we evaluated the transcriptomic heterogeneity using the top principal components and demonstrate that the AD lesional skin presents a higher degree of heterogeneity than psoriasis (Figure 1b). By using psoriasis lesional skin as a reference, these results provide molecular and mechanistic support to complement previous clinical- or genetic-based observations for the heterogeneity of AD (Cole et al., 2014; Weidinger and Novak, 2016).

Differential expression (DE) (Supplementary Table S4 online) analyzes were conducted to identify differentially expressed genes (DEGs) (false discovery rate ≤5% and \(|\log_2(\text{fold change})| ≥ 1\). Our results are concordant with previous studies in psoriasis (Li et al., 2014; Tsoi et al., 2015) that demonstrated large number of DEGs (up/down = 2,502/4,261) when comparing normal versus psoriasis lesional skin (Figure 1c). The DE analysis for normal versus AD lesional skin revealed a substantially larger number of DEGs (up/down = 1,529/1,921) compared to previous studies (Gittler et al., 2012; Rodriguez et al., 2014; Suarez-Farinas et al., 2011, 2015), suggesting that the sample size and the deepsequencing can enhance the statistical power for more robust characterization of AD lesional skin. In fact, when comparing the changes in AD skin measured in previous microarray studies, we demonstrated the limited ability of microarray technology to detect low-expressing transcripts (Supplementary Figure S2 online). For instance, IL13, an upregulated cytokine in AD, could only be identified as significant in our study, but not in previous microarray experiments.

Strikingly, we identified a large number of DEGs (n = 2,800) shared between AD and psoriasis lesional skin (Figure 1d; corresponding to 41% and 81% of the psoriasis and AD DEGs, respectively), and the correlations of the magnitudes in dysregulation in lesional skin in both diseases were significantly correlated (Figure 1e; Spearman \(r = 0.8; P < 1 \times 10^{-16}\)). In contrast, direct comparison between AD versus psoriasis lesional skin showed lower number of DEGs (up/down = 1,259/771) than those revealed in the normal versus lesional comparison. The DE results for comparing nonlesional with lesional AD skin illustrate similar findings (Supplementary Table S4). Despite modest differences between normal and nonlesional skin of psoriasis (also vs. non-lesional skin of AD), the dysregulation in uninvolved skin was significantly correlated with those in lesional skin (\(r = 0.55\) and 0.64 for psoriasis and AD, respectively; \(P < 1 \times 10^{-16}\), suggesting that nonlesional skin exhibit subtle pro-inflammatory responses and epidermal dysregulation that are further manifested in lesional skin. Interestingly, we also observed significant correlation (\(r = 0.4; P < 1 \times 10^{-16}\)) between the magnitudes of dysregulation in the psoriatic and AD non-lesional skin (Figure 1f). These evaluations identified gene profiles that mark progression from normal to uninvolved to inflamed skin and illustrated a surprisingly high degree of concordance between the gene expression in lesional AD and psoriatic skin.

We demonstrated previously that a higher proportion of long noncoding RNAs tend to be differentially expressed in the psoriatic lesional skin than protein-coding genes, probably due to differences in cellular compositions (Tsoi et al., 2015). We observed the same trend in this study (i.e., 30% long noncoding RNA vs. 21% protein-coding are DEGs) (Supplementary Figure S3 online). Interestingly, a higher proportion of long noncoding RNAs tended to be differentially expressed in lesional AD skin (17% vs. 11%). These results were not influenced by the large number of DEGs overlapping between AD and psoriasis skin, as we still demonstrated consistent results in both AD-only and psoriasis-only DEGs (Figure 1g). Notably, while “Immune” and “T-cell receptor” was the gene category with the largest proportion of DEGs in any of the control versus lesional skin comparisons, it represents the smallest proportion in the direct psoriasis versus AD DE analysis, suggesting that the diseases share overlapping inflammatory pathways and responses. Despite otherwise distinct clinical features of AD and psoriasis, these two diseases have significant overlap in their molecular architecture, particularly in categories related to inflammatory responses.

**Common and specific molecular and cellular features of AD and psoriasis**

We identified 469 significant functions enriched in the common DEGs for lesional skin in AD/psoriasis, including functions associated with immunologic responses, and IFN and cytokine signaling pathways (top functions in Figure 2a; full list in Supplementary Table S5 online). When comparing the enrichment results between the AD-only versus the psoriasis-only DEGs, we observed distinct patterns of significance (Figure 2b). Functions involved in growth factor activity and myeloid dendritic cell activation were enriched in AD-only DEGs (Supplementary Table S5), while genes involved in
functions like major histocompatibility complex class I antigen processing/presentation, cell cycle, and arginine/proline metabolism were enriched in psoriasis-only DEGs (Figure 2c). Nerve growth factor levels have been shown to reflect the severity of itching and eruption in AD (Yamaguchi et al., 2009), and perturbation of proline/arginine metabolism has been demonstrated in psoriasis (Kamleh et al., 2015). Functions that were enriched among genes dysregulated in the direct AD versus psoriasis comparison included “carbohydrate derivative binding,” “collagen metabolic process” (Supplementary Table S5), among the significant functions encompassing AD-specific DEGs included activity and composition of “chloride channels,” “regulation of fibroblast growth factor receptor signaling pathway,” “regulation of macrophage activation,” and “GABA ERK1/2 receptor activity” (Figure 2d). Interestingly, recent experimental data indicate that dysregulation of epidermal chloride channels (Selmann et al., 2018), fibroblast growth factor receptor signaling (Sulcova et al., 2015), as well as P38/ERK MAPK signaling pathways (Tan et al., 2017), all impact epidermal barrier function and cutaneous homeostasis, and might be involved in the pathogenesis of AD.

The DE analysis demonstrated overlap between the transcriptomes of nonlesional skin from AD and psoriasis patients (Figure 1f), when each was compared to normal control skin. Interestingly, each of the AD and psoriatic non-lesional skin DE gene sets were enriched for 32 significant functions/pathways, and >50% (17) of these overlapped, including “keratinocytes differentiation” (P \leq 5 \times 10^{-11}) and “cytokine activity” (P \leq 1 \times 10^{-3}) (Supplementary Table S6 online). Interestingly, for “keratinocyte differentiation” the same genes (i.e., LCE3A/D, S100A7) were dysregulated in the same direction in both types of nonlesional skin, with S100A7 and other precursor genes of cornified cell envelope (e.g., SPRR2A/B) having a higher expression in psoriasis nonlesional skin than AD nonlesional skin, and late cornified genes (i.e., LCE3A/D) showing no difference between the two nonlesional types. While both nonlesional skin types have alterations in common genes associated with keratinocyte differentiation, the changes were greater in psoriasis. For “cytokine activity,” different dysregulated genes were involved in psoriasis nonlesional (CCL4, IL19, IL36A/G) and AD nonlesional (CCL13, CCL18, IL13, IL20, IL26).
We evaluated the profiles for 33 cytokines expressed in our skin samples to further characterize the inflammatory signatures (Figure 3). Cytokines encoding IL-17 (IL17A/F), IL-36 (IL36A/G), and IFN responses (IFNG) had the most prominent expression in lesional psoriatic skin (at least sevenfold more highly expressed in psoriasis compared to AD, respectively). It is noteworthy that IL-36, which has been studied in psoriasis extensively (Mahil et al., 2017), is also elevated in AD lesional skin (Figure 3, Supplementary Figure S4 online). IL-20 family cytokines, which have been shown to contribute to epidermal proliferation (i.e., IL19, IL20, IL22, IL24) were elevated in both AD and psoriasis. The Th2 signature gene, IL13, was the most distinctive markers for AD. In strong contrast to IL13, mRNA expression of IL4 was detectable in only 40% of the AD lesional samples, and at very low expression levels (Supplementary Table S7 online), suggesting that AD is an IL-13—rather than IL-4—driven disease (Tazawa et al., 2004).

We then analyzed the enrichment of DEGs near different immune cell-specific active enhancer marks (defined by H3K27ac) using recent large-scale epigenomic data sets (Farh et al., 2015; Roadmap Epigenomics Consortium et al., 2015) to infer cell type origins for these transcripts (Figure 4a, Supplementary Table S8 online). The shared DEGs in the lesional skin of AD and psoriasis were highly enriched in Th1/Th2/Th17/monocyte marks, while the Th2 epigenomic signature was enriched among the AD-only DEGs. The nearby enhancers of regulatory T and memory T cells were enriched in the common AD/psoriasis DEGs, while no enrichment in naïve T cells was observed. Among the DEGs in the direct psoriasis versus AD comparison, enrichment for CD8⁺ memory cells in both the AD-elevated and the psoriasis-elevated genes were observed separately. Using quantitative immunohistochemistry (Figure 4b; Supplementary Figure S5 online and Supplementary Table S9 online), we illustrated that the proportions of CD8⁺ and CD8⁺ chromatin signature (Figure 4) are consistent with previous suggestions that CD8⁺ T cells may play important roles in inflammatory cytokine production in AD, as well as psoriasis (Hijnen et al., 2013).
Using independent RNA-seq generated from keratinocytes stimulated by different cytokines, we correlated the gene expression responses against our disease DEGs (Figure 5a). When correlating cytokine responses in keratinocytes against the direct psoriatic versus AD lesional skin comparison, genes with higher expressions in psoriasis tend to be induced by IL-17A, IL-17A/TNF, IL-36α, β, γ, and IFN-α; while genes with higher expressions in AD tend to be induced by IL-4 and IL-13. These results indicate that while both diseases might have contribution from IL-17A/IL-36/TNF/IFN-α responses, the magnitude and the degree of these responses are less intense in AD, and vice versa for IL-4/IL-13. In fact, by using IL-17A, IL-4, and IL-13 responses as features, we could separate AD from psoriasis (Figure 5b). Notably, the uninvolved skin samples from both AD and psoriasis moved toward the same cytokine—response axes as the affected AD and psoriatic skin, respectively.

Transcriptomic analysis to provide translational inference for AD

We were able to provide near perfect classification for AD and psoriasis (area under the receiver operating curve = 0.99 for left out data set) using only the IL17A, IL13, and IL36G expression profiles (Figure 6a), the classification performance concords with results from previous studies using the expressions of NOS2 and CCL27 as biomarkers (Garzorz-Stark et al., 2016; Quaranta et al., 2014). Despite the modest differences between healthy skin and nonlesional AD skin, as well as healthy skin versus nonlesional psoriatic skin, we could obtain good classification: area under the receiver operating curve = 0.86 for AD uninvolved skin using IL13, EBI3, IL26, IL20, IL5, IL36A, IL36G, and area under the receiver operating curve = 0.91 for psoriasis uninvolved skin using IL36G, IL19, IL18, IL36A, EBI3, IL13 (Supplementary Table S10 online). These results reinforce the presence of a “pre-inflammatory” signature in both uninvolved AD and psoriasis skin. Notably, while both IL17A and IL36G were upregulated in psoriatic lesional skin, only IL36G, but not IL17A, was selected as one of the features differentiating normal from psoriatic nonlesional skin. Indeed, despite concordance between psoriasis uninvolved skin and IL17A induced effect in Figure 5a, IL36G, but not IL17A, was significantly upregulated in nonlesional psoriatic skin.

We hypothesized that with our larger transcriptomic cohort in AD lesional skin profiled using the higher-resolution RNA sequencing technology, we would obtain more powerful associations for disease severity compared with previous work (Tejasvi et al., 2013). Analyzing expression of cytokines change with the severity index (Psoriasis Area Severity Index for psoriasis; SCORAD for AD) (Oranje, 2011) together revealed that IL17A, IL23A, IL27, and EBI3 were correlated (P < 0.05) with Psoriasis Area Severity Index (all but IL27 was positively correlated), and IL13 and TSLP were positively correlated (P < 0.05) with SCORAD (Supplementary Figure S6 online and Supplementary Table S11 online). While these correlations are only nominally significant, we observed strong global correlations when associating the expression changes in...
lesional skin and the severity indices across the whole transcriptome for both associations (Figure 6b, 6c; Spearman correlation $r = 0.4; P < 2 \times 10^{-16}$), an observation that has not been described previously. Notably, the two Spearman correlation values from the above calculations were also highly correlated, particularly for the common AD/psoriasis DEGs ($r = 0.3$ for whole genome vs. $r = 0.6$ for common DEGs; Figure 6d).

Finally, we investigated current medication gene targets for AD, and evaluated for enrichment among the different sets of DEGs. This demonstrated that existing drug targets for AD were highly enriched among DEGs in AD skin ($P < 5 \times 10^{-14}$; Supplementary Figure S7 online, Supplementary Table S12 online). Extending this analysis to other drugs and determining whether their gene targets were enriched with AD DEGs, we observed enrichment for several steroid agents (budesonide, triamcinolone, beclomethasone, alclometasone dipropionate) (false discovery rate <1%; observed to expected ratio $\geq 4$). Most notably, tofacitinib, a Jak inhibitor, which has recent success in treating AD (Bissonnette et al., 2016), proved to be highly significant ($P = 5.4 \times 10^{-18}$; observed to expected ratio = 4.9). These results demonstrate that transcriptomic data can be a valuable resource to reveal novel drug targets.

**DISCUSSION**

AD is associated with epidermal barrier dysfunction, for example, due to mutations in the FLG gene (O’Regan et al., 2008), type 1 allergic responses, with an increased susceptibility towards both bacterial and viral infections (Weidinger et al., 2018; Wollenberg et al., 2003). In addition, AD is also associated with atopic features, such as asthma and allergic rhinitis. In line with this, 25% of the AD patients studied here carried an FLG mutation, and 60% suffered from comorbid asthma and/or rhinitis (Supplementary Table S2). In contrast, psoriasis typically is not associated with a general skin barrier dysfunction or allergic features and is relatively resistant to skin infection. Although these two diseases are readily distinguished using clinical criteria, it has been suggested that AD and psoriasis exist on a “spectrum” (Guttman-Yassky and
Krueger, 2017) and amendable to shared treatment approaches (Guttman-Yassky et al., 2017) based on shared immunologic processes and the observation that with increased chronicity AD takes on histologic features that resemble psoriasis with associated prominence of Th1/IFN-γ responses (Guttman-Yassky et al., 2011). Our study provides insights into the shared and unique molecular features of psoriasis and AD; although the analyses revealed overlap of transcripts relevant for inflammation in both unaffected and affected skin, we identified distinct sets of gene features that clearly separate both diseases, such as IL-13/IL-4 response in AD versus IL-17 responses in psoriasis.

AD has for a long time been considered a Th2 disease characterized by IL-4 cytokine responses (Leung and Bieber, 2003). A surprising finding was that the mRNA expression of IL4 was detectable in only 40% of AD samples. While we found prominent enrichment for “IL-4 responses” in AD skin (Figure 5), IL-4 has a short in vivo half-life, and shares much of its biology with the cytokine IL-13, and IL-13 shares the heterodimeric receptor IL-4R/IL-13Rα with IL-4 (Mueller et al., 2002). It is likely that the “IL-4 signature” is largely attributable to IL-13 and related to the excessive amounts of IL-13 in AD skin (Figure 3). In fact, IL-4/IL-13 inhibition through blockade of the IL-4R by
dupilumab has been shown in several studies to be a highly effective treatment for AD (Blauvelt et al., 2017; Simpson et al., 2016), whereas no clinical trials directly targeting IL-4 in AD have ever been published. Consistent with our findings, anti–IL-13 targeted therapy with tralokinumab, led to early and sustained improvement in AD symptoms (Wollenberg et al., 2018).

We acknowledge that AD is a heterogeneous disease and thus transcriptomic profiling results can vary as lesions evolve. In this study, we recruited only adult patients with a chronic AD/psoriasis using established criteria (for AD, the American Academy of Dermatology Consensus Criteria). Only AD lesions with a reported duration of >72 hours corresponding to the subacute to chronic state were selected in order to minimize potential differences between “early” versus “established” lesions. Future study that can consider the dynamics and fluctuations of the AD lesion through longitudinal assessments can have potential to provide a more thorough understanding of the disease trajectory, as well as its heterogeneous nature.

In summary, this study provides a detailed view of the mechanisms operating in psoriasis and AD and suggests that AD is primarily an IL-13–dominant disease. Our data demonstrate a shared “core transcriptome” shared between AD and psoriasis, primarily characterized by enriched Th1/IFN responses. However, therapeutics targeting those shared processes have been largely disappointing in AD. Given the opposing polarization signal in AD (toward IL-13 responses) and psoriasis (toward IL-17 responses), our data are consistent with the notion that these diseases represent overlapping, yet distinct diseases, and do not fit the view that these diseases exist on an extended spectrum.

MATERIAL AND METHODS
Sample preparation
Informed written consent was obtained from human subjects under a protocol approved by the local ethics board at the University Hospital Schleswig-Holstein, Kiel, Germany (reference: A100/12). AD or psoriasis was diagnosed on the basis of a skin examination by experienced dermatologists according to standard criteria (for AD, the American Academy of Dermatology Consensus Criteria were used). Five-millimeter skin punch biopsies from the extremities (under local anesthesia) were obtained. Total RNA was isolated from PAXgene fixed tissue samples...
using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s specifications. Preceding RNA isolation all samples were disrupted using innuSPEED Lysis Tubes W (1.4- to 1.6-mm steel beads and 3.5-mm ceramic beads) in a SpeedMill Plus (3 x 1-minute intervals) together with 600 µl RLT-Plus-Buffer (Qiagen) including β-mercaptoethanol and additionally homogenized with QIAshredder spin-columns. Only samples with a concentration of >50 ng/µl, an optical density 260/280 ≥1.8, and a RNA integrity number >7 were included in subsequent library preparation and sequencing. RNA samples were prepared for sequencing using the Illumina Truseq Stranded total RNA Protocol in combination with the Rib-o-Zero rRNA Removal Kit (Illumina) and sequenced on the HiSeq2500 in pools of 10 samples with 2 x 125 bp.

RNA-seq data analysis
Illumina (San Diego, CA) standard primers were trimmed, and the quality of the data was assessed using FastQC, version 0.11.3 (Andrews, 2010). Paired reads were mapped to the human reference genome (b37) using STAR (Dobin et al., 2013), only uniquely mapped read pairs were retained. Number of reads for each gene was counted using HTSeq (Anders et al., 2015), only genes with on average ≥1 read/sample were used in our analysis. Trimmed mean of M-values (TMM) was used to normalize the RNA-seq data (Robinson and Oshlack, 2010), and we applied voom transformation of M-values (TMM) was used to normalize the RNA-seq data average was counted using HTSeq (Anders et al., 2015), only genes with on average ≥1 read/sample were used in our analysis. Trimmed mean of M-values (TMM) was used to normalize the RNA-seq data (Robinson and Oshlack, 2010), and we applied voom transformation to model the mean-variance relationship of the expression data (Law et al., 2014). We conducted differential expression analysis between different conditions using empirical Bayes linear model as implemented in the limma package (Ritchie et al., 2015). We identified cell-type specificity using H3K27ac peak signals (Farh et al., 2015) and cytokine signatures using different cytokine stimulated keratinocytes transcriptome profiles. The details of the data and approaches are available in the Supplementary Material online.

ORCID
James T. Elder: http://orcid.org/0000-0003-4215-3294

CONFLICT OF INTEREST
Johann E. Gudjonsson serves as Advisory Board for Novartis and MiRagen, and has received research support from AbbVie, SunPharma, and Genentech. Spiro Getios is an employee and stakeholder of GlaxoSmithKline, and this study is in no way influenced by the work at GlaxoSmithKline. The remaining authors state no conflict of interest.

ACKNOWLEDGMENTS
This work was supported by an award from the Else Kröner-Fresenius-Stiftung (2014_A270) (SW, ER), by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany’s excellence Strategy—EXC 22167-390884018, by grants from the German Federal Ministry of Education and Research (BMBF) within the framework of the e-Med research and funding concept (sysINFLAME, grant 01ZX1306a) and the ComorbibSysMed, grant 01ZX1510 (SS), and by the Bockenham Endowment Fund (LCT, MRS, IT, JEG), by the National Institute of Arthritis and Musculoskeletal and Skin Diseases: AR060802 (JEG), AR054966 (ITE), and AR072129 (LCT), and National Institute of Allergy and Infectious Diseases under Award Number R01-AR06 (JEG), and the A. Alfred Taubman Medical Research Institute Kenneth and Frances Eisenberg Emerging Scholar Award (JEG). LCT is supported by the Dermatology Foundation, Arthritis National Research Foundation, and National Psoriasis Foundation.

Data accession: National Center for Biotechnology Information Gene Expression Omnibus accession: GSE121212.

AUTHOR CONTRIBUTIONS
SW designed the study. SW and NV contributed with clinical samples and data. ER, UW, and AF performed experiments. LCT, FD, HB, and SS performed quality control and processed the RNA-seq data. LCT, WRS, KR, MP, and YG conducted the bioinformatics analysis of the processed data. MS, RU, BEPW, SS, LCT, and JEG contributed to the keratinocyte RNA-seq experimental data or the analysis. ER, LCT, PH, EM, JTE, AF, JEG, and SW contributed to the biological inference of the analysis results. LCT, JEG, and SW wrote the manuscript.

SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at www.jidonline.org, and at https://doi.org/10.1016/j.jid.2018.12.018.

REFERENCES